Real Estate Investments - Gyrodyne's remaining real estate investments include 13.8 acres in Cortlandt Manor with a 31,000 square foot medical center and 63 acres in Flowerfield with a 135,000 rentable square foot industrial park[119]. - The Flowerfield property has received preliminary approval for subdivision into eight lots, but is currently subject to an Article 78 Proceeding that could delay final approvals[124][125]. - The Town of Cortlandt has approved a Medical Oriented Zoning District for the Cortlandt Manor property, allowing for a total density of 154,000 square feet, including 150,000 square feet for medical use[130]. - The company is focusing on enhancing the development flexibility of its Flowerfield and Cortlandt Manor properties, with ongoing discussions with local authorities for potential entitlements[144]. - The Cortlandt Manor property is proposed to include 150,000 square feet of medical use and 4,000 square feet of ancillary retail, with anticipated site plan approval in Q4 2024[142]. - The company is exploring development projects at Flowerfield that currently fall within "as of right to build" zoning[144]. Strategic Plans and Goals - The company aims to enhance the net value of its properties and maximize shareholder returns through strategic asset disposition and timely distributions[118]. - Gyrodyne's dual strategy involves pursuing entitlement opportunities to increase development flexibility and enhancing lease values to boost overall property value[121]. - Gyrodyne plans to aggressively market its properties and negotiate purchase agreements, aiming to complete sales by year-end 2024, although external factors may impact this timeline[132]. - The company is committed to managing its real estate portfolio to improve cash flow while increasing market values[127]. - Gyrodyne intends to dissolve after completing asset dispositions and settling debts, with distributions to shareholders dependent on the successful sale of properties[117]. - The company is pursuing entitlements and density approvals for its properties, with a total density of 154,000 square feet designated for the Cortlandt Manor property[180]. Financial Projections and Distributions - The company expects a cash balance of approximately $30.03 million by December 31, 2024, equating to future distributions of $20.25 per share based on 1,482,680 common shares outstanding[133]. - The estimated net assets in liquidation as of September 30, 2023, were $30,028,537, equating to $20.25 per share based on 1,482,680 shares outstanding[169]. - Following the issuance of restricted stock under the Stock Plan, pro forma net assets in liquidation are estimated at $32,730,822, or $20.79 per share based on 1,574,308 shares outstanding[166]. - The company anticipates completing the liquidation process by December 31, 2024, although this timeline may change due to various external factors[174]. - The company expects to distribute approximately $30.03 million to shareholders from the liquidation process[205]. - The estimated distributions per share have decreased by $0.23 due to fees and expenses related to shareholder activism and professional fees[191]. Costs and Expenses - The company incurred approximately $400,300 in land entitlement costs during the nine months ended September 30, 2023, with an estimated additional $1,077,600 in costs through December 31, 2024[136]. - The entitlement costs for the nine months ended September 30, 2023, were approximately $343,000, covering architectural, engineering, legal, and survey expenses[148]. - The company has estimated general and administrative expenses of approximately $2.98 million, excluding final liquidation costs[197]. - The company has incurred entitlement costs of approximately $57,200 for the nine months ended September 30, 2023, related to the ownership and development of the Cortlandt Manor property[143]. Market Conditions and Risks - The company faces risks including ongoing litigation, market conditions, and regulatory approvals that could affect its strategic plans and timelines[110][126]. - The pandemic has negatively impacted demand for office and hotel developments, influencing the Company's subdivision strategy to enhance development flexibility[149]. - The Flowerfield subdivision remains subject to an Article 78 Proceeding, which could take two years or more to resolve[178]. Lease Activity - During the nine months ended September 30, 2023, the Company executed ten lease renewals totaling approximately 16,500 square feet, generating annual revenue of approximately $241,000[162]. - The Company experienced three lease terminations, resulting in a loss of $8,960 in monthly rent and approximately $99,000 in annual revenue from one lease[162]. - Four expansions were executed, comprising approximately 2,300 square feet, contributing $40,000 in annual revenue and approximately $185,000 in total commitments[163]. Cash Position - The company had cash and cash equivalents of approximately $2.68 million as of September 30, 2023, which is expected to be adequate for its ongoing liquidation efforts[205]. - The cash balance at the end of the liquidation period is estimated to be $2.68 million, with adjustments for future cash inflows and outflows[192]. - The company is considering seeking supplemental funding to strengthen its cash position during the liquidation process[205]. Accounting and Valuation - All assets are stated at their estimated net realizable value based on independent appraisals and other sales value indications[174]. - The company has made significant estimates regarding the net realizable value from real estate sales and the costs associated with pursuing entitlements[185]. - Management has concluded that newly issued accounting pronouncements will not materially impact the company's consolidated financial statements since it reports on a liquidation basis[189]. - As of September 30, 2023, the company's net assets totaled approximately $30.03 million, down from $30.37 million as of December 31, 2022[194]. - The estimated distributions per common share are approximately $20.25 based on the September 30, 2023 net assets, compared to $20.48 as of December 31, 2022[194].

Cash Position and Distributions - Gyrodyne expects to have a cash balance of approximately $29.87 million by December 31, 2024, prior to any future special distributions, equating to future distributions of $20.14 per share based on 1,482,680 common shares outstanding [125]. - The company plans to dissolve after completing the disposition of all real property assets and settling any debts, with distributions to shareholders dependent on the successful sale of assets [110]. - If available cash and asset sale proceeds are insufficient to meet obligations, cash distributions to shareholders may be eliminated [126]. - As of June 30, 2023, the company's net assets in liquidation are estimated at $29,866,455, resulting in estimated liquidating distributions of approximately $20.14 per common share based on 1,482,680 shares outstanding [183]. - The cash balance at the end of the liquidation period is estimated to be $3.1 million, with adjustments for various costs and revenues expected through December 31, 2024 [184]. - The company estimates total gross cash proceeds from the sale of its assets to be approximately $53.67 million, leading to an estimated distributable cash of approximately $29.87 million from the liquidation [196]. Real Estate Assets and Development - The company aims to complete the disposition of its real estate assets and make timely distributions to shareholders, with a focus on enhancing the net value of its properties [112]. - Gyrodyne's remaining real estate investments include 63 acres in Flowerfield and 13.8 acres in Cortlandt Manor, with the latter designated for a total density of 154,000 square feet, including 150,000 square feet for medical use [118][122]. - The Flowerfield property has received preliminary approval for subdivision into eight lots, but is currently subject to an Article 78 Proceeding that could delay the process [117][121]. - The Town of Cortlandt adopted a SEQRA Findings Statement on March 20, 2023, establishing a MOD designation for the property, allowing for a total density of 154,000 square feet [137]. - The Company is focusing on positioning properties for sale with all entitlements to maximize development flexibility while minimizing risk [130]. - The Company is exploring potential real estate development projects for the Flowerfield property, which currently falls within "as of right to build" zoning [139]. - The Company anticipates that subdivision and site plan approval could be received by mid-2024, contingent on contract timing [137]. - The company is focused on negotiating purchase agreements and securing final approvals to maximize property values and distributions [174]. Financial Performance and Costs - The Company incurred approximately $342,000 in land entitlement costs during the six months ended June 30, 2023, primarily for engineering, legal fees, and real estate taxes [129]. - An estimated additional $862,000 in land entitlement costs is expected through December 31, 2024, with $105,000 of this amount informally deferred by vendors [129]. - The entitlement costs for the six months ended June 30, 2023, associated with the ownership and development of the Cortlandt Manor property were approximately $50,700 [138]. - The entitlement costs for the six months ended June 30, 2023, were approximately $291,800, covering architectural, engineering, legal, and survey expenses [143]. - Corporate expenditures for the same period amounted to $1,487,718, with additional capital expenditures of $115,531 [203]. - The company estimates that the final liquidation and dissolution costs will amount to approximately $1.51 million [189]. Risks and Challenges - Risks affecting the company's future results include ongoing litigation, community activism, and economic factors such as inflation and rising interest rates [105][106]. - The company has no assurance that the timeline for liquidation will be met due to factors outside its control, including ongoing legal proceedings [170]. - The COVID-19 pandemic has caused delays in local government approvals, affecting the completion of important stages in securing entitlements [150]. - The healthcare industry, which comprises the Company’s tenants, faces increased regulation that could materially impact their operations and ability to pay rent [146]. - The U.S. Federal Reserve raised interest rates a total of seven times in 2022 and four times in 2023, significantly increasing market interest rates and potentially leading to a recession [153]. Lease Activity - During the six months ended June 30, 2023, the Company executed 7 lease renewals totaling approximately 8,700 square feet, generating annual revenue of approximately $125,000 and total commitments of approximately $258,000 [157]. - The Company experienced two terminations of land leases, resulting in a loss of $8,960 in monthly rent [157]. - Four expansions were executed, comprising approximately 2,300 square feet, generating $40,000 in annual revenue and approximately $185,000 in total commitments [158]. - The company reported $1,562,118 in rent and reimbursements, with a net operating income of $731,543 for the six months ended June 30, 2023 [203]. Funding and Financial Strategy - The company is considering seeking supplemental funding to strengthen its cash position during the liquidation process [126]. - Major vendors have informally agreed to defer payment on 50% of their fees until the first subdivided lot is sold, aiding cash flow management [195]. - The company secured a $4.95 million term loan in September 2021, which was used to pay off a previous debt facility [199].

Financial Projections and Liquidation - Gyrodyne expects to have a cash balance of approximately $30.31 million by December 31, 2024, prior to any future special distributions, equating to estimated distributions of $20.44 per share based on 1,482,680 common shares outstanding [125]. - The Company estimates net assets in liquidation as of March 31, 2023, at $30,309,439, resulting in estimated distributions of approximately $20.44 per common share based on 1,482,680 shares outstanding [178]. - The Company anticipates the completion of the liquidation process by December 31, 2024, although this timeline may be affected by factors beyond its control [170]. - The cash balance at the end of the liquidation period is estimated to be $3.68 million, with adjustments for various costs and revenues expected until December 31, 2024 [179]. - The estimated cash proceeds from rental operations are projected to total $1.98 million, net of commissions and rental costs [183]. - The Company estimates total gross cash proceeds from the sale of its assets to be approximately $53.67 million, with an estimated distributable cash of approximately $30.31 million from the liquidation [191]. - Major vendors have informally agreed to defer payment on 50% of their fees until the first subdivided lot is sold, aiding cash flow during liquidation [190]. - The Company is considering seeking supplemental funding through a new credit facility or pro-rata rights offering to strengthen its cash position during liquidation [190]. - The Company anticipates that cash and cash equivalents, along with proceeds from asset sales, will exceed the costs to complete the liquidation [192]. - The Company has not experienced any significant credit risk on cash as of March 31, 2023, and maintains bank account balances exceeding FDIC insurance limits [193]. - General and administrative expenses, excluding final liquidation costs, are estimated to be $4.26 million [184]. Real Estate Development and Entitlements - The company aims to complete the disposition of its real estate assets and make timely distributions to shareholders, with a focus on enhancing the net value of its properties [112]. - Gyrodyne's remaining real estate investments include 63 acres in Flowerfield and 13.8 acres in Cortlandt Manor, with the latter designated for 154,000 square feet of total density, including 150,000 square feet for medical use [118][122]. - The company is pursuing entitlement opportunities for its properties to increase development flexibility and maximize value for shareholders [114]. - The Flowerfield property has received preliminary approval for subdivision into eight lots, but is currently subject to an Article 78 proceeding that could delay the process [117][121]. - The Company is pursuing entitlements for Flowerfield and Cortlandt Manor properties to enhance development flexibility, with a focus on minimizing risk [129]. - The Town of Cortlandt adopted a SEQRA Findings Statement on March 20, 2023, establishing a MOD designation for the property, allowing for a total density of 154,000 square feet [135]. - The Company has committed resources toward market research and feasibility studies to maximize the value of the Cortlandt Manor property, which includes a proposed medical office campus [131]. - The Company is exploring potential real estate development projects at Flowerfield that fall within "as of right to build" zoning, while seeking additional entitlements from the Town of Smithtown [137]. - The Company filed a pre-subdivision application for the Flowerfield property, which was initially processed as a nine-lot subdivision but ultimately approved as an eight-lot subdivision in 2021 [138]. - The Company is pursuing entitlements and density approvals for the Flowerfield property, which involves extensive analysis and could materially impact property value [163]. - The Town of Smithtown Planning Board granted preliminary approval to divide the Flowerfield property into eight lots on March 30, 2022 [164]. - The Company is addressing technical comments from various agencies regarding the Final Subdivision Plans, with final approval expected in the second half of 2023 [141]. - The Company believes subdivision approval for Flowerfield will be received in the second half of 2023, and for Cortlandt Manor by mid-2023, contingent on contract timing [169]. Operational Challenges and Market Conditions - Risks include ongoing litigation related to the Article 78 proceeding and market conditions affecting the sale of assets [106][120]. - The COVID-19 pandemic has adversely impacted the timeliness of local government approvals, causing delays in securing entitlements [149]. - The Company is facing increased regulatory scrutiny in the healthcare industry, which could impact the marketability of its properties [145]. - The U.S. Federal Reserve raised interest rates a total of seven times in 2022 and three times in 2023, affecting the economic outlook and potentially leading to a recession [152]. - The Company is actively reviewing operating activities for possible cost reductions throughout the liquidation process [192]. - There have been no significant changes in market risk since the last report filed on March 30, 2023 [196]. Financial Performance and Revenue - The Company incurred approximately $253,000 in land entitlement costs during Q1 2023, with an estimated additional $952,000 expected through December 31, 2024 [128]. - The entitlement costs for the three months ended March 31, 2023, associated with the ownership and development of the Cortlandt Manor property were approximately $45,500 [136]. - The entitlement costs for the three months ended March 31, 2023, were approximately $207,400 [142]. - During the three months ended March 31, 2023, the Company executed 5 renewals comprising approximately 6,700 square feet, generating annual revenue of approximately $96,000 and total commitments of approximately $229,000 [156]. - The Company experienced one termination of a tenant resulting in a loss of $6,260 in monthly rent [156]. - The decrease in net assets from January 1 to March 31, 2023, was $58,060, primarily due to additional general and administrative fees [186]. - As of March 31, 2023, the Company had cash and cash equivalents totaling approximately $3.68 million, which is expected to be adequate for funding the liquidation process [191]. - The Company secured a $4.95 million term loan on September 15, 2021, to pay off previous debt, with $1,050,000 outstanding at that time [194].

Financial Projections and Distributions - As of December 31, 2022, Gyrodyne expects a cash balance of approximately $30.37 million by December 31, 2024, which would equate to future distributions of $20.48 per share based on 1,482,680 common shares outstanding[32]. - The estimated distributions to shareholders are based on values as of December 31, 2022, and include some but not all potential value from entitlement efforts[32]. - The company acknowledges that distributions to shareholders may be delayed or reduced due to various uncertainties, including market conditions and legal challenges[121]. - Future special distribution declarations will depend on actual cash flow and proceeds from property sales[208]. Property Development and Entitlements - Gyrodyne's strategy includes pursuing entitlements for Flowerfield and Cortlandt Manor to enhance property values and maximize shareholder returns[23]. - The Flowerfield property subdivision received preliminary approval on March 30, 2022, but is currently subject to an Article 78 Proceeding that could delay final approvals[26][27]. - The Company anticipates that the process of negotiating purchase agreements and securing final approvals will culminate by year-end 2024[31]. - The Company is focusing on positioning properties for sale with all entitlements to achieve increased development flexibility with minimal risk[40]. - The Company is exploring potential real estate development projects in Flowerfield that fall within "as of right to build" zoning[49]. - The Company anticipates that subdivision and site plan approval for the Cortlandt Manor property could be received by mid-2024[47]. - The Company has been in discussions with the Town of Smithtown regarding entitlements and special permits for the Flowerfield property[49]. - The Company intends to enhance property values through entitlement opportunities and strategic sales of properties[207]. Financial Position and Liabilities - The Company incurred approximately $315,500 in land entitlement costs during the year ended December 31, 2022, with an estimated additional $1.2 million in costs expected through December 31, 2024[39]. - The total liability for estimated costs during liquidation is $14,758,728, which includes costs associated with the sale of real estate and litigation[125]. - The Company has an outstanding principal balance of $2,075,005 on a non-revolving credit line as of December 31, 2022, with a fixed interest rate of 3.85%[84]. - The Company has a second loan with an outstanding balance of $2,838,477 as of December 31, 2022, also at a fixed interest rate of 3.85%[85]. - The Company secured a loan for $4.95 million on September 15, 2021, part of which was used to pay off existing working capital loans[70]. - The Company secured a $4.95 million term loan with Signature Bank, bearing an interest rate of 3.75% for five years, with an option to extend for an additional five years[87]. - As of December 31, 2022, the outstanding balance of the Mortgage Loan was $4,846,601[88]. - The Company is considering seeking supplemental funding to strengthen its cash position during the liquidation process[33]. Rental Income and Occupancy - As of December 31, 2022, the annual base rent at Flowerfield is approximately $1,706,000 with an occupancy rate of 83%[60]. - The annual base rent at Cortlandt Manor is approximately $908,000 with an occupancy rate of 92% as of December 31, 2022[61]. - Rental income from the Company's three largest tenants represented approximately 23%, 21%, and 9% of total rental income for the year ended December 31, 2022[97]. - The company's projected annual rental revenues for 2023 from not-for-profit corporations and tenants not affiliated with SBU or SBU Hospital are expected to be approximately $1,020,000, accounting for 39% of total revenues[145]. - The existing leases with Stony Brook University Hospital and affiliates represent approximately 27% of the company's annual rental revenue for 2023[146]. - The largest medical tenant in the Cortlandt Manor Medical Center accounts for 28% of the company's annual rental revenue for 2023[147]. - The total annual rent for all locations is $2,613,700, with an overall occupancy rate of 85%[192]. Risks and Challenges - The company is facing community opposition that could delay the process of obtaining necessary entitlements and approvals for property value enhancement[117]. - The company is defending against an Article 78 proceeding that could extend the timeline for securing entitlements and selling properties[119]. - The company faces risks associated with tenant defaults, which could adversely affect cash flow and distributions to shareholders[143]. - Increased operating costs due to inflation could reduce the estimated net assets and sales prices of properties[156]. - The company may incur costs to comply with environmental laws, which could increase operating expenses[150]. - The ongoing impact of the COVID-19 pandemic may continue to affect the company's operations and timelines for property sales and distributions[152]. - The company's common shares are thinly traded, leading to potential volatility and limited liquidity in the market[158]. - A sustained increase in interest rates could negatively impact property valuations and lower sales proceeds from future dispositions[156]. - The company has a history of operating losses and anticipates future operating losses, with no guarantee of income to distribute other than proceeds from property sales[160]. Company Operations and Compliance - The Company operates in one segment: the ownership and management of industrial and medical office buildings[111]. - The Company believes all properties are in compliance with environmental regulations and is not aware of any contamination requiring material capital expenditure[93]. - The Company carries comprehensive insurance coverage on all properties, including liability, property, and business interruption insurance[95]. - The Company has four employees as of December 31, 2022 and 2021[109]. - The average age of buildings at Flowerfield is approximately 62 years, and 32 years at Cortlandt Manor[189]. - The Company has committed resources to market research and feasibility studies to maximize property value in Cortlandt Manor[42]. - The Company is in compliance with loan covenants as of December 31, 2022[86].

Financial Projections and Distributions - As of September 30, 2022, the estimated cash balance for Gyrodyne is projected to be approximately $22.87 million by December 31, 2024, equating to future distributions of $15.42 per share based on 1,482,680 common shares outstanding[126]. - The estimated distributions to shareholders are based on values as of September 30, 2022, and include some potential value from ongoing entitlement efforts[126]. - Estimated liquidating distributions per share are approximately $15.42 based on net assets in liquidation of $22,869,716 as of September 30, 2022, down from $15.53 per share as of December 31, 2021[183]. - The cash balance at the end of the liquidation period is estimated to be $4.4 million, which will be used to fund efforts to maximize property values and facilitate asset sales[197]. - Total gross cash proceeds from the sale of assets are estimated at approximately $42.5 million, with distributable cash from liquidation estimated at $22.87 million[197]. Property Development and Entitlements - Gyrodyne's strategy includes enhancing the value of its properties in Flowerfield and Cortlandt Manor through entitlement opportunities and lease value enhancement[112]. - The Flowerfield property has received preliminary approval to be subdivided into eight lots, pending certain conditions[120]. - The Company anticipates final approvals for subdivision applications for Flowerfield and Cortlandt Manor in 2023, allowing for the identification of potential purchasers[124]. - The ongoing Article 78 Proceeding could delay the timeline for final approvals and property sales, potentially extending beyond 2024[122]. - The Company is focusing on maximizing pre-construction values for properties by pursuing necessary entitlements while considering attractive offers from potential buyers[130]. - The Company is exploring development projects at Flowerfield that fall within "as of right to build" zoning and may seek additional entitlements from the Town of Smithtown[137]. - The Company is proposing a two-phase medical office campus with limited retail in the MOD, which has not yet been formally adopted[134]. - An alternate mixed-use plan for the Cortlandt property includes 83,500 square feet of medical office space and 160 multi-family residential units[135]. - The Company anticipates the final Environmental Impact Statement (EIS) for the Cortlandt property will be accepted in Q4 2022, with MOD designation expected in Q1 2023[136]. - The Company is pursuing entitlements and density approvals, with the timeline for completion potentially extending due to various external factors[167]. Financial Performance and Revenue - The company reported net operating income of $914,279 for the nine months ended September 30, 2022, with total rents and reimbursements of $2,251,369 and operating costs of $1,337,090[200]. - During the nine months ended September 30, 2022, the Company executed two new leases and 15 renewals, generating annual revenue of approximately $61,600 and $410,400 respectively[160]. - The Company incurred commission fees of approximately $27,300 related to new and extended leases during the same period[160]. - Approximately 41% of the Company's 2022 projected annual rental revenues are from tenants not affiliated with a major hospital[148]. - The Company deferred approximately $118,000 of rental revenue due to tenants closed under the "New York State on PAUSE" Executive Order, with all deferred rent expected to be collected[156]. Costs and Expenses - The Company incurred approximately $282,000 in land entitlement costs during the nine months ended September 30, 2022, with an estimated additional $1.09 million expected through December 31, 2024[129]. - The entitlement costs for the Cortlandt property for the nine months ended September 30, 2022, were approximately $76,000[133]. - The entitlement costs for the Flowerfield property for the nine months ended September 30, 2022, were approximately $206,000[141]. - The company estimates that general and administrative expenses, excluding final liquidation costs, will total approximately $4.99 million[192]. - The Company has deferred approximately $1,114,000 of land development fees and other professional fees until the first post-subdivision property lot is sold[158]. Strategic Intent and Future Plans - Gyrodyne intends to dissolve after the disposition of all real property assets and the settlement of debts, with liquidating distributions to shareholders thereafter[113]. - The Company has a dual strategy to manage risk while maximizing returns for shareholders through the enhancement of property values[117]. - The Company intends to complete the liquidation process by December 31, 2024, although this timeline is subject to various external factors[174]. - The pandemic has negatively impacted demand for office and hotel developments, influencing the Company's subdivision plan at Flowerfield[142]. - The healthcare industry, which comprises the Company's tenants, is facing increased regulation that could materially impact their operations and the marketability of the properties[144]. Risk Management - The Company has not experienced any significant credit risk on cash as of September 30, 2022, and maintains bank account balances exceeding FDIC insurance limits[201].

FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37547 Gyrodyne, LLC (Exact name of registrant as specified in its charter) New York 46-3838291 (State or other jurisdiction of incorporation or ...

FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 001-37547 Gyrodyne, LLC (Exact name of registrant as specified in its charter) New York 46-3838291 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ___________________. Commission file number: 333-191820 GYRODYNE, LLC (Exact name of registrant as specified in its charter) (State or other jur ...

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 For the transition period from ____________ to ____________ Commission file number 001-37547 Gyrodyne, LLC (Exact name of registrant as specified in its charter) New York 46-3838291 (State or other j ...

FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 001-37547 Gyrodyne, LLC (Exact name of registrant as specified in its charter) New York 46-3838291 (State or other jurisd ...